WA
LCTX icon

WFG Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

WFG Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-558
Closed -$2K – 2272
2013
Q3 		$2K Hold
558
– – ﹤0.01% 1939
2013
Q2 		$2K Buy
+558
New +$1.79K ﹤0.01% 1851

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

WFG Advisors's LCTX Position: Q4 2013 in Review

WFG Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2013, closing a stake of 558 shares — an estimated $2K sold.

WFG Advisors first reported a position in LCTX in Q2 2013 and held it in 2 quarters. The position peaked at $2K in Q3 2013. 58 funds tracked by Wall St. Rank hold LCTX as of Q4 2013.

  • WFG Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2013 after selling out during the quarter.
  • WFG Advisors sold 558 Lineage Cell Therapeutics shares in Q4 2013, an estimated $2K.
  • WFG Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 2 quarters.
  • WFG Advisors's Lineage Cell Therapeutics position peaked at $2K in Q3 2013.
  • 58 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2013.

Based on WFG Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.